

Sabine Semrau

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/980817/publications.pdf>

Version: 2024-02-01

50
papers

746
citations

516710

16
h-index

642732

23
g-index

56
all docs

56
docs citations

56
times ranked

931
citing authors

#	ARTICLE	IF	CITATIONS
1	Patterns of care analysis for salivary gland cancer: a survey within the German Society of Radiation Oncology (DEGRO) and recommendations for daily practice. <i>Strahlentherapie Und Onkologie</i> , 2022, 198, 123-134.	2.0	6
2	Induction chemoimmunotherapy followed by CD8+ immune cell-based patient selection for chemotherapy-free radioimmunotherapy in locally advanced head and neck cancer. , 2022, 10, e003747.		23
3	Transient Enlargement in Meningiomas Treated with Stereotactic Radiotherapy. <i>Cancers</i> , 2022, 14, 1547.	3.7	3
4	Radio(chemo)therapy in anaplastic thyroid cancer—high locoregional but low distant control rates—A monocentric analysis of a tertiary referral center. <i>Strahlentherapie Und Onkologie</i> , 2022, 198, 994-1001.	2.0	0
5	Pathologic response after induction chemo-immunotherapy with single or double immune checkpoint inhibition in locally advanced head and neck squamous cell carcinoma (HNSCC): Expansion cohorts of the CheckRad-CD8 trial.. <i>Journal of Clinical Oncology</i> , 2022, 40, 6064-6064.	1.6	2
6	Randomized phase III trial of induction chemotherapy followed by chemoradiotherapy or chemotherapy alone for nonresectable locally advanced pancreatic cancer: First results of the CONKO-007 trial.. <i>Journal of Clinical Oncology</i> , 2022, 40, 4008-4008.	1.6	39
7	Questionnaire-based detection of immune-related adverse events in cancer patients treated with PD-1/PD-L1 immune checkpoint inhibitors. <i>BMC Cancer</i> , 2021, 21, 314.	2.6	9
8	Implementation of Double Immune Checkpoint Blockade Increases Response Rate to Induction Chemotherapy in Head and Neck Cancer. <i>Cancers</i> , 2021, 13, 1959.	3.7	11
9	Prognostic and predictive value of PD-L1 expression and tumour infiltrating lymphocytes (TILs) in locally advanced NSCLC treated with simultaneous radiochemotherapy in the randomized, multicenter, phase III German Intergroup lung Trial (GILT). <i>Lung Cancer</i> , 2021, 160, 17-27.	2.0	10
10	Reduction of Elective Radiotherapy Treatment Volume in Definitive Treatment of Locally Advanced Head and Neck Cancer—Comparison of a Prospective Trial with a Revised Simulated Contouring Approach. <i>Journal of Clinical Medicine</i> , 2021, 10, 4653.	2.4	1
11	Predictive Value of Multiparametric MRI for Response to Single-Cycle Induction Chemo-Immunotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 734872.	2.8	9
12	Long-Term Follow-Up of Patients Receiving Neoadjuvant Treatment Modalities for Soft Tissue Sarcomas of the Extremities. <i>Cancers</i> , 2021, 13, 5244.	3.7	1
13	Relevance of the time interval between surgery and adjuvant radio (chemo) therapy in HPV-negative and advanced head and neck carcinoma of unknown primary (CUP). <i>BMC Cancer</i> , 2021, 21, 1236.	2.6	2
14	Single-cycle induction chemotherapy before chemoradiotherapy or surgery in functionally inoperable head and neck squamous cell carcinoma: 10-year results. <i>European Archives of Oto-Rhino-Laryngology</i> , 2020, 277, 245-254.	1.6	6
15	Classification of three prognostically different groups of head and neck cancer patients based on their metabolic response to induction chemotherapy (IC-1). <i>Oral Oncology</i> , 2020, 100, 104479.	1.5	7
16	Safety and efficacy of single cycle induction treatment with cisplatin/docetaxel/durvalumab/tremelimumab in locally advanced HNSCC: first results of CheckRad-CD8. , 2020, 8, e001378.		51
17	Prospective evaluation of the prognostic value of immune-related adverse events in patients with non-melanoma solid tumour treated with PD-1/PD-L1 inhibitors alone and in combination with radiotherapy. <i>European Journal of Cancer</i> , 2020, 140, 55-62.	2.8	23
18	Prospective Evaluation of All-lesion Versus Single-lesion Radiotherapy in Combination With PD-1/PD-L1 Immune Checkpoint Inhibitors. <i>Frontiers in Oncology</i> , 2020, 10, 576643.	2.8	13

#	ARTICLE	IF	CITATIONS
19	The Role of Plastic Reconstructive Surgery in Surgical Therapy of Soft Tissue Sarcomas. <i>Cancers</i> , 2020, 12, 3534.	3.7	13
20	FSRT vs. SRS in Brain Metastases – Differences in Local Control and Radiation Necrosis – A Volumetric Study. <i>Frontiers in Oncology</i> , 2020, 10, 559193.	2.8	29
21	The influence of postoperative complications on long-term prognosis in patients with colorectal carcinoma. <i>International Journal of Colorectal Disease</i> , 2020, 35, 1055-1066.	2.2	19
22	Magnetic resonance imaging for brain stereotactic radiotherapy. <i>Strahlentherapie Und Onkologie</i> , 2020, 196, 444-456.	2.0	43
23	Dose Reduction to the Swallowing Apparatus and the Salivary Glands by De-Intensification of Postoperative Radiotherapy in Patients with Head and Neck Cancer: First (Treatment Planning) Results of the Prospective Multicenter DIREKHT Trial. <i>Cancers</i> , 2020, 12, 538.	3.7	5
24	Early Mortality of Brain Cancer Patients and its Connection to Cytomegalovirus Reactivation During Radiochemotherapy. <i>Clinical Cancer Research</i> , 2020, 26, 3259-3270.	7.0	13
25	A multicenter phase II trial of the combination cisplatin/ docetaxel/durvalumab/tremelimumab as single-cycle induction treatment in locally advanced HNSCC (CheckRad-CD8 trial).. <i>Journal of Clinical Oncology</i> , 2020, 38, 6519-6519.	1.6	3
26	Patient's quality of life after surgery and radiotherapy for extremity soft tissue sarcoma - a retrospective single-center study over ten years. <i>Health and Quality of Life Outcomes</i> , 2019, 17, 170.	2.4	12
27	Salivary gland carcinoma (SGC) with perineural spread and/or positive resection margin – high locoregional control rates after photon (chemo) radiotherapy - experience from a monocentric analysis. <i>Radiation Oncology</i> , 2019, 14, 68.	2.7	8
28	Time course of pain response and toxicity after whole-nerve-encompassing LINAC-based stereotactic radiosurgery for trigeminal neuralgia – a prospective observational study. <i>Strahlentherapie Und Onkologie</i> , 2019, 195, 745-755.	2.0	7
29	Paragangliomas of the Head and Neck. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2019, 42, 818-823.	1.3	7
30	Is there a patient population with squamous cell carcinoma of the head and neck region who might benefit from de-intensification of postoperative radiotherapy?. <i>Strahlentherapie Und Onkologie</i> , 2019, 195, 482-495.	2.0	6
31	Sinonasal Leiomyosarcoma: Clinicopathological Analysis of Nine Cases with Emphasis on Common Association with Other Malignancies and Late Distant Metastasis. <i>Head and Neck Pathology</i> , 2018, 12, 463-470.	2.6	14
32	The influence of tumour site on prognosis in metastatic colorectal carcinomas with primary tumour resection. <i>International Journal of Colorectal Disease</i> , 2018, 33, 1215-1223.	2.2	7
33	Stereotactic radiotherapy of vestibular schwannoma. <i>Strahlentherapie Und Onkologie</i> , 2017, 193, 200-212.	2.0	27
34	Management of advanced hypopharyngeal and laryngeal cancer with and without cartilage invasion. <i>Auris Nasus Larynx</i> , 2017, 44, 333-339.	1.2	22
35	Study of the impact of cytomegalovirus-encephalopathy on survival of brain cancer patients undergoing treatment with radio(chemo)therapy.. <i>Journal of Clinical Oncology</i> , 2017, 35, 2036-2036.	1.6	0
36	Frequent occurrence of therapeutically reversible CMV-associated encephalopathy during radiotherapy of the brain. <i>Neuro-Oncology</i> , 2016, 18, 1664-1672.	1.2	21

#	ARTICLE	IF	CITATIONS
37	Intraabdominal ALK-positive anaplastic large cell lymphoma in a patient with neurofibromatosis type 1. <i>Histopathology</i> , 2016, 68, 752-754.	2.9	2
38	Bayesian Cure Rate Modeling of Local Tumor Control: Evaluation in Stereotactic Body Radiation Therapy for Pulmonary Metastases. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 94, 841-849.	0.8	19
39	Recurrent glioblastoma: who receives tumor specific treatment and how often?. <i>Journal of Neuro-Oncology</i> , 2016, 128, 85-92.	2.9	14
40	Primary glioblastoma multiforme tumors and recurrence. <i>Strahlentherapie Und Onkologie</i> , 2016, 192, 146-155.	2.0	34
41	Frequent occurrence of therapeutically reversible cmv-associated encephalopathy during radiotherapy of the brain.. <i>Journal of Clinical Oncology</i> , 2016, 34, e13507-e13507.	1.6	0
42	Single-cycle induction chemotherapy followed by chemoradiotherapy or surgery in patients with head and neck cancer: What are the best predictors of remission and prognosis?. <i>Cancer</i> , 2015, 121, 1214-1222.	4.1	27
43	Older patients with inoperable non-small cell lung cancer. <i>Strahlentherapie Und Onkologie</i> , 2014, 190, 1125-1132.	2.0	22
44	A model to predict the feasibility of concurrent chemoradiotherapy with temozolomide in glioblastoma multiforme patients over age 65.. <i>Journal of Clinical Oncology</i> , 2014, 32, 2040-2040.	1.6	0
45	Results of chemoselection with short induction chemotherapy followed by chemoradiation or surgery in the treatment of functionally inoperable carcinomas of the pharynx and larynx. <i>Oral Oncology</i> , 2013, 49, 454-460.	1.5	27
46	Feasibility, Toxicity, and Efficacy of Short Induction Chemotherapy of Docetaxel Plus Cisplatin or Carboplatin (TP) Followed by Concurrent Chemoradiotherapy for Organ Preservation in Advanced Cancer of the Hypopharynx, Larynx, and Base of Tongue. <i>Strahlentherapie Und Onkologie</i> , 2011, 187, 15-22.	2.0	35
47	Baseline Cardiopulmonary Function as an Independent Prognostic Factor for Survival of Inoperable Non-Small-Cell Lung Cancer After Concurrent Chemoradiotherapy: A Single-Center Analysis of 161 Cases. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 79, 96-104.	0.8	21
48	Stage III: Definitive Chemoradiotherapy. <i>Frontiers of Radiation Therapy and Oncology</i> , 2009, 42, 122-134.	1.4	6
49	6-Year Experience of Concurrent Radiochemotherapy with Vinorelbine Plus a Platinum Compound in Multimorbid or Aged Patients with Inoperable Non-Small Cell Lung Cancer. <i>Strahlentherapie Und Onkologie</i> , 2007, 183, 30-35.	2.0	34
50	Oral Vinorelbine and Cisplatin with Concomitant Radiotherapy in Stage III Non-Small Cell Lung Cancer (NSCLC): A Feasibility Study. <i>Oncology Research and Treatment</i> , 2006, 29, 137-142.	1.2	12